Full Press Release Details
Halozyme Therapeutics
Hill + Knowlton Strategies
Halozyme Reports First Quarter 2013 Financial Results
SAN DIEGO, May 8, 2013 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013.
"With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex brand, I am pleased with the steps we are making towards our near term revenue drivers," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "Moreover, over the next 8 weeks, we will present a first-look at clinical data from our innovative pipeline products, PEGPH20 and HTI-501."
Highlights of Halozyme's first quarter activities and recent events include:
First Quarter 2013 Financial Highlights
Halozyme will webcast its Quarterly Update Conference Call today at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, Ph.D., Halozyme's President and Chief Executive Officer, will lead the call. During the call, the Company plans to provide further details underlying its first quarter 2013 financial results. The call will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and the recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 413625.
Upcoming Conferences
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning potential product launches and near-term revenue opportunities, the Company's expected presentation of data from the PEGPH20 Phase 1b study in pancreatic cancer and Phase 2 HTI-501 trial in cellulite, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2013.
Halozyme Therapeutics, Inc.
Condensed Consolidated Statements of Operations
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2013 | 2012 | |||||||
| REVENUES: | ||||||||
| Product sales, net | $ | 1,508,594 | $ | 187,411 | ||||
| Revenues under collaborative agreements | 10,324,946 | 7,252,768 | ||||||
| Total revenues | 11,833,540 | 7,440,179 | ||||||
| OPERATING EXPENSES: | ||||||||
| Cost of product sales | 738,971 | 70,761 | ||||||
| Research and development | 22,034,437 | 15,891,109 | ||||||
| Selling, general and administrative | 7,555,905 | 6,618,707 | ||||||
| Total operating expenses | 30,329,313 | 22,580,577 | ||||||
| OPERATING LOSS | (18,495,773 | ) | (15,140,398 | ) | ||||
| Investment and other income | 54,988 | 21,217 | ||||||
| Interest expense | (847,584 | ) | - | |||||
| NET LOSS | $ | (19,288,369 | ) | $ | (15,119,181 | ) | ||
| Basic and diluted net loss per share | $ | (0.17 | ) | $ | (0.14 | ) | ||
| Shares used in computing basic and diluted | ||||||||
| net loss per share | 112,416,792 | 107,589,514 |
Halozyme Therapeutics, Inc.
Condensed Consolidated Balance Sheets
| March 31, | December 31, | ||||||||
| 2013 | 2012 | ||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 39,017,804 | $ | 99,501,264 | |||||
| Marketable securities, available-for-sale | 48,408,220 | - | |||||||
| Accounts receivable, net | 10,375,733 | 15,703,087 | |||||||
| Inventories | 2,737,387 | 2,670,696 | |||||||
| Prepaid expenses and other assets | 10,571,334 | 12,752,888 | |||||||
| Total current assets | 111,110,478 | 130,627,935 | |||||||
| Property and equipment, net | 3,975,052 | 3,700,462 | |||||||
| Prepaid expenses and other assets | 1,280,765 | - | |||||||
| Restricted cash | 500,000 | 400,000 | |||||||
| Total Assets | $ | 116,866,295 | $ | 134,728,397 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 2,884,794 | $ | 2,271,689 | |||||
| Accrued expenses | 9,177,574 | 7,783,447 | |||||||
| Deferred revenue, current portion | 6,326,158 | 8,891,017 | |||||||
| Current portion of long-term debt | 1,362,055 | - | |||||||
| Total current liabilities | 19,750,581 | 18,946,153 | |||||||
| Deferred revenue, net of current portion | 34,318,481 | 34,954,966 | |||||||
| Long-term debt, net | 28,323,233 | 29,661,680 | |||||||
| Lease financing obligation | 1,450,000 | 1,450,000 | |||||||
| Deferred rent, net of current portion | 906,091 | 861,879 | |||||||
| Other long term liability | 436,849 | - | |||||||
| Stockholders' equity: | |||||||||
| Common stock | 113,143 | 112,709 | |||||||
| Additional paid-in capital | 349,459,065 | 347,314,658 | |||||||
| Accumulated other comprehensive loss | (29,131 | ) | - | ||||||
| Accumulated deficit | (317,862,017 | ) | (298,573,648 | ) | |||||
| Total stockholders' equity | 31,681,060 | 48,853,719 | |||||||
| Total Liabilities and Stockholders' Equity | $ | 116,866,295 | $ | 134,728,397 |